BETHESDA, Md., Jan. 5 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, provides an outlook on key events anticipated for the year 2009.
Micromet intends to provide an update on its research and development programs at the following events:
-- April 12 to 16, 2009: Update on several preclinical BiTE antibodies at the American Association for Cancer Research (AACR) in Denver, CO;
-- April 24, 2009: The company will hold an R&D meeting in New York, NY for investors and analysts to provide a review of its product pipeline;
-- May 29 to June 5, 2009: Update on a phase 1b clinical trial combining adecatumumab with docetaxel in late stage metastatic breast cancer patients at the annual meeting of the American Society for Clinical Oncology (ASCO) in San Francisco, CA;
-- June 4 to 7, 2009: Update on phase 2 clinical trial with blinatumomab in acute lymphoblastic leukemia (ALL) patients at the 14th Congress of the European Hematology Association (EHA) in Berlin, Germany;
-- September 20 to 24, 2009: First interim data from a phase 1 clinical trial with MT110, an EpCAM-targeting BiTE antibody, in patients with metastatic gastro-intestinal and lung cancers at the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO) in Berlin, Germany;
-- December 5 to 8, 2009: Update on a phase 2 clinical trial with blinatumomab in ALL patients and final results from a phase 1 clinical trial in late stage NHL at the annual meeting of the American Society for Hematology (ASH) in New Orleans, LA.
Additional expected milestones in 2009
|SOURCE Micromet, Inc.|
Copyright©2009 PR Newswire.
All rights reserved